Related Experiment Video
Updated: Mar 26, 2026
10:26
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
9.0K
High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma
Sara Correia Marques1, Benyamin Ranjbar2, Maria Bach Laursen3
1Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Experimental Hematology
|February 9, 2016
Summary
MicroRNAs, especially miR-34a, can predict treatment response in diffuse large B-cell lymphoma (DLBCL). High miR-34a expression indicates sensitivity to doxorubicin, offering potential as a biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Diffuse large B-cell lymphoma (DLBCL) treatment resistance affects 40% of patients.
- Novel biomarkers are crucial for improving DLBCL patient outcomes.
- The R-CHOP regimen is the standard immunochemotherapy for DLBCL.
Purpose of the Study:
- Identify microRNAs (miRNAs) associated with doxorubicin sensitivity in DLBCL.
- Evaluate miR-34a as a predictive and prognostic biomarker for DLBCL patients.
- Investigate the role of miR-34a in doxorubicin resistance.
Main Methods:
- Global miRNA expression profiling and dose-response screens in 15 DLBCL cell lines.
- Functional in vitro studies and in vivo analysis in a retrospective clinical cohort.
- Analysis of miR-34a expression in relation to resistance gene signatures (REGS) and B cell-associated gene signatures (BAGS).
Main Results:
- High miR-34a expression correlated with doxorubicin sensitivity in DLBCL cell lines.
- Upregulation of miR-34a enhanced doxorubicin sensitivity in vitro.
- High miR-34a expression demonstrated prognostic impact on overall survival.
- miR-34a expression varied based on DLBCL subsets and differentiation.
- FOXP1 identified as a target of miR-34a, potentially mediating doxorubicin sensitivity.
Conclusions:
- miR-34a serves as a potential predictive biomarker for doxorubicin response in DLBCL.
- miR-34a may function as a prognostic biomarker for DLBCL patients.
- Targeting miR-34a or its downstream effectors could offer novel therapeutic strategies for DLBCL.
